Last edition
News about "Ascletis Pharma"
Ascletis Pharma Completes US Phase 2 Enrollment for ASC30 GLP-1R Agonist
Ascletis Pharma completes US Phase 2 enrollment for ASC30, an oral GLP-1R agonist for diabetes. The 13-week study evaluates safety, efficacy, and tolerability in 100 patients, with topline results expected in Q3 2026.
Ascletis Pharma | 27/04/2026 | By News Bureau
Ascletis Receives FDA IND Clearance for Phase II ASC30 Diabetes Study
Ascletis has received US FDA IND clearance to initiate a 13-week phase-II, randomised, double-blind, placebo-controlled, multi-centre study evaluating the efficacy, safety and tolerability of its oral small-molecule GLP-1 candidate ASC30 in participants with diabetes, with enrollment expected to begin in the first quarter of 2026.
Ascletis Pharma | 05/01/2026 | By News Bureau | 118
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy